In France, HAS considers that the ERVEBO vaccine can be used as part of its marketing authorization in people aged 18 years or more. For professionals likely to be exposed, the HAS confirms the recommendations of the HCSP which consists in vaccinating:
- professionals traveling to epidemic areas, depending on the level of exposure expected after analysis with the organizers of future tasks;
- professionals in health establishments likely to take charge of a case of EVD in France (ESR), in particular those who are in direct contact with the patient or his biological products;
- professionals in the context of post-exposure to contaminated fluids; according to the procedures defined and detailed by the HCSP in its opinion published in 2020.